ES2648864T3 - Método de administración de fármacos de PTH, PTHRP y péptidos relacionados - Google Patents

Método de administración de fármacos de PTH, PTHRP y péptidos relacionados Download PDF

Info

Publication number
ES2648864T3
ES2648864T3 ES12773751.8T ES12773751T ES2648864T3 ES 2648864 T3 ES2648864 T3 ES 2648864T3 ES 12773751 T ES12773751 T ES 12773751T ES 2648864 T3 ES2648864 T3 ES 2648864T3
Authority
ES
Spain
Prior art keywords
aib29
matrix
microprojections
leu23
microprojection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12773751.8T
Other languages
English (en)
Spanish (es)
Inventor
Gary Hattersley
Kris J. HANSEN
Amy S. DETERMAN
Ying Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Radius Health Inc
Original Assignee
3M Innovative Properties Co
Radius Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co, Radius Health Inc filed Critical 3M Innovative Properties Co
Application granted granted Critical
Publication of ES2648864T3 publication Critical patent/ES2648864T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0023—Drug applicators using microneedles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
ES12773751.8T 2011-04-22 2012-04-20 Método de administración de fármacos de PTH, PTHRP y péptidos relacionados Active ES2648864T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161478466P 2011-04-22 2011-04-22
US201161478466P 2011-04-22
US201161578120P 2011-12-20 2011-12-20
US201161578120P 2011-12-20
PCT/US2012/034510 WO2012145665A2 (en) 2011-04-22 2012-04-20 Method of drug delivery for pth, pthrp and related peptides

Publications (1)

Publication Number Publication Date
ES2648864T3 true ES2648864T3 (es) 2018-01-08

Family

ID=47042187

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12773751.8T Active ES2648864T3 (es) 2011-04-22 2012-04-20 Método de administración de fármacos de PTH, PTHRP y péptidos relacionados

Country Status (14)

Country Link
US (6) US20130006217A1 (enExample)
EP (2) EP2699252B1 (enExample)
JP (2) JP6033280B2 (enExample)
KR (1) KR20140047043A (enExample)
CN (1) CN103917242A (enExample)
AU (2) AU2012245301B2 (enExample)
BR (1) BR112013027153A2 (enExample)
CA (1) CA2833571A1 (enExample)
ES (1) ES2648864T3 (enExample)
IL (1) IL228942A0 (enExample)
MX (1) MX2013012349A (enExample)
RU (1) RU2013151314A (enExample)
SG (1) SG194570A1 (enExample)
WO (1) WO2012145665A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE030072T2 (en) 2010-05-12 2017-04-28 Radius Health Inc Therapeutic prescriptions
US20130158482A1 (en) * 2010-07-26 2013-06-20 Seventh Sense Biosystems, Inc. Rapid delivery and/or receiving of fluids
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
WO2012064802A1 (en) 2010-11-09 2012-05-18 Seventh Sense Biosystems, Inc. Systems and interfaces for blood sampling
KR102143482B1 (ko) 2011-11-30 2020-08-11 쓰리엠 이노베이티브 프로퍼티즈 컴파니 펩티드 치료제 및 아미노산을 포함하는 마이크로니들 장치, 이의 제조 및 사용 방법
CN104602752A (zh) * 2012-08-30 2015-05-06 帝人株式会社 涂布有药物组合物的微针阵列
ES3055185T3 (en) 2014-03-28 2026-02-10 Univ Duke Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
CA2977812A1 (en) * 2015-03-03 2016-09-09 Radius Health, Inc. Uses of pthrp analogue in reducing fracture risk
KR20250152679A (ko) 2015-04-29 2025-10-23 래디어스 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
CN108025042A (zh) * 2015-07-06 2018-05-11 董正欣 PTHrP类似物的新型制剂
WO2017062727A1 (en) 2015-10-09 2017-04-13 3M Innovative Properties Company Zinc compositions for coated microneedle arrays
KR20180067573A (ko) * 2015-10-09 2018-06-20 라디우스 헬쓰, 인코포레이티드 PTHrP 유사체의 제형, 이의 경피 패취, 및 이의 용도
US10568937B2 (en) * 2016-04-18 2020-02-25 Radius Health, Inc. Formulations of abaloparatide, transdermal patches thereof, and uses thereof
MX389702B (es) 2016-06-22 2025-03-20 Ellipses Pharma Ltd Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
CA3045458A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
JP7481115B2 (ja) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形性形態
US9968767B1 (en) 2017-10-10 2018-05-15 King Saud University Combination microarray patch for drug delivery and electrochemotherapy device
WO2019232283A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
MX2020013713A (es) 2018-07-04 2021-03-02 Radius Pharmaceuticals Inc Formas polimorficas de rad1901-2hcl.
EP3924328A1 (en) 2019-02-12 2021-12-22 Radius Pharmaceuticals, Inc. Processes and compounds
EP4110371A1 (en) 2020-01-24 2023-01-04 Radius Health, Inc. Methods of stimulating bone growth with abalopartide and denosumab
JP2023523952A (ja) 2020-04-28 2023-06-08 ティコナ・エルエルシー マイクロニードルアセンブリ
US20230210762A1 (en) * 2020-05-01 2023-07-06 Emergex USA Corporation Transdermal drug delivery devices having psilocybin, lysergic acid diethylamide or 3,4-methylenedioxymethamphetamine coated microprotrusions
WO2022149066A1 (en) * 2021-01-05 2022-07-14 Radius Health, Inc. Treatment of long bone fractures with abaloparatide
US12178979B2 (en) 2021-10-13 2024-12-31 Satio, Inc. Dermal patch for delivering a pharmaceutical
US12214346B2 (en) 2021-10-13 2025-02-04 Satio, Inc. Dermal patch with a diagnostic test strip
US11877848B2 (en) 2021-11-08 2024-01-23 Satio, Inc. Dermal patch for collecting a physiological sample
US12053284B2 (en) 2021-11-08 2024-08-06 Satio, Inc. Dermal patch for collecting a physiological sample
US12023156B2 (en) 2021-10-13 2024-07-02 Satio, Inc. Dermal patch for collecting a physiological sample
US12048543B2 (en) 2021-11-08 2024-07-30 Satio, Inc. Dermal patch for collecting a physiological sample with removable vial
US11452474B1 (en) 2021-04-14 2022-09-27 Satio, Inc. Dual lever dermal patch system
US11964121B2 (en) 2021-10-13 2024-04-23 Satio, Inc. Mono dose dermal patch for pharmaceutical delivery

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544949B1 (en) * 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5969095A (en) 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
CA2313698C (en) * 1997-12-11 2008-04-15 Alza Corporation Device for enhancing transdermal agent flux
DE69806963T2 (de) * 1997-12-11 2002-11-21 Alza Corp., Mountain View Vorrichtung zur erhöhung des transdermalen wirkstoffeflusses
US6091975A (en) * 1998-04-01 2000-07-18 Alza Corporation Minimally invasive detecting device
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
JP2007535337A (ja) * 2003-10-28 2007-12-06 アルザ・コーポレーシヨン 被覆された微小突起による治療用ペプチドおよびタンパクのポリマー接合体の送達
ES2377647T3 (es) * 2003-10-31 2012-03-29 Alza Corporation Aplicador auto-actuado para ordenamiento de microproyecciones
KR20070010115A (ko) * 2003-11-13 2007-01-22 알자 코포레이션 경피전달용 조성물 및 장치
US7556821B2 (en) 2004-05-13 2009-07-07 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US8057842B2 (en) 2004-11-18 2011-11-15 3M Innovative Properties Company Method of contact coating a microneedle array
US8632801B2 (en) * 2005-12-28 2014-01-21 Alza Corporation Stable therapeutic formulations
AU2007225056A1 (en) * 2006-03-15 2007-09-20 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
US9119945B2 (en) 2006-04-20 2015-09-01 3M Innovative Properties Company Device for applying a microneedle array
US8048383B2 (en) * 2006-04-20 2011-11-01 Velocys, Inc. Process for treating and/or forming a non-Newtonian fluid using microchannel process technology
US7803770B2 (en) * 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
BRPI0719821B8 (pt) * 2006-10-03 2021-05-25 Ipsen Pharma Sas composição estável na armazenagem apropriada para administração a pacientes
EP2119469B1 (en) * 2007-02-06 2014-05-14 Hisamitsu Pharmaceutical Co., Inc. Microneedle device for diagnosis of allergy
US9549746B2 (en) * 2007-09-28 2017-01-24 The Queen's University Of Belfast Delivery device and method
WO2009054988A1 (en) * 2007-10-23 2009-04-30 Alza Corporation Transdermal sustained release drug delivery
EP2052736A1 (en) * 2007-10-26 2009-04-29 Nycomed Danmark ApS Parathyroid hormone formulations und uses thereof
KR101668502B1 (ko) 2008-11-04 2016-10-21 아스카 세이야쿠 가부시키가이샤 난포자극호르몬 함유 수성 조성물
US20110172609A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device

Also Published As

Publication number Publication date
NZ618003A (en) 2016-05-27
CN103917242A (zh) 2014-07-09
JP6033280B2 (ja) 2016-11-30
US20140046293A1 (en) 2014-02-13
AU2016216584A1 (en) 2016-09-01
BR112013027153A2 (pt) 2016-11-29
JP2014517825A (ja) 2014-07-24
MX2013012349A (es) 2014-07-09
US20130006217A1 (en) 2013-01-03
KR20140047043A (ko) 2014-04-21
US20190290738A1 (en) 2019-09-26
EP3332799A1 (en) 2018-06-13
US20170189493A1 (en) 2017-07-06
WO2012145665A2 (en) 2012-10-26
IL228942A0 (en) 2013-12-31
CA2833571A1 (en) 2012-10-26
RU2013151314A (ru) 2015-05-27
WO2012145665A3 (en) 2014-04-24
US20140046292A1 (en) 2014-02-13
SG194570A1 (en) 2013-12-30
EP2699252A2 (en) 2014-02-26
JP2017036323A (ja) 2017-02-16
EP2699252B1 (en) 2017-10-25
AU2012245301B2 (en) 2016-05-19
EP2699252A4 (en) 2015-05-27
US20210052705A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
ES2648864T3 (es) Método de administración de fármacos de PTH, PTHRP y péptidos relacionados
AU2012245301A1 (en) Method of drug delivery for PTH, PTHrP and related peptides
JP6919087B2 (ja) アバロパラチドの製剤、その経皮パッチ、およびその使用
JP6867379B2 (ja) ＰＴＨｒＰ類似体の製剤、その経皮パッチ、およびその使用
Seeherman et al. rhBMP-2/calcium phosphate matrix accelerates osteotomy-site healing in a nonhuman primate model at multiple treatment times and concentrations
ES2574761T3 (es) Formulaciones para el tratamiento de la diabetes
JP2021088600A (ja) ポリマーを含まない微細構造物を含むマイクロアレイ、製造方法および使用方法
ES2775498T3 (es) Formulación en polvo nasal para el tratamiento de la hipoglucemia
Wang et al. Injection of ROS-Responsive Hydrogel Loaded with IL-1β-targeted nanobody for ameliorating myocardial infarction
TW201427684A (zh) 胰島素長效調配物
ES2927067T3 (es) Abaloparatida combinada con alendronato para la reducción de las fracturas óseas no vertebrales
CN109862906A (zh) 用于口服的活性剂的制剂
JP2008518941A (ja) 大腸連続性を伴う短腸症候群患者の治療
JP6873387B2 (ja) 創傷治癒に対するａｐｃ類似体の使用
Depreter et al. Comparative pharmacoscintigraphic and pharmacokinetic evaluation of two new formulations of inhaled insulin in type 1 diabetic patients
NZ618003B2 (en) Method of drug delivery for pth, pthrp and related peptides
HK1192138B (en) Method of drug delivery for pth, pthrp and related peptides
HK1192138A (en) Method of drug delivery for pth, pthrp and related peptides
US20260000712A1 (en) Method for modulating glucagon-like peptide 1 (glp-1) agonist induced muscle loss
JP2007515375A (ja) 多系統萎縮症におけるヒト成長ホルモンの使用
Iyire Buccal transmucosal delivery of large molecule therapeutics using orally disintegrating tablet technology
Assessment AOD-9604: The Fat Loss Fragment of Growth Hormone-Research, Mechanism & Clinical Data